Merribeth Morin first joined PATH in 2011 as a program advisor in research and development (R&D) and now leads the transmission-blocking vaccine (TBV) program for MVI. She oversees the clinical and non-clinical TBV efforts to develop vaccines that will be key for the elimination and eradication of malaria. She also leads the evaluation technologies work for the development and utilization of assays needed to confidently assess vaccine efficacy.
Merribeth has a number of years of experience in the biotechnology industry, many of them spent developing and validating assays used for biosafety and product release testing. She has assisted many companies and organizations with the design of safety testing strategies for regulatory submissions, both to US and European agencies.
She holds a PhD in virology from Harvard University, under the mentorship of Bernie Fields, as well as an MS in microbiology from Cornell University and a BS in biology from Rensselaer Polytechnic Institute. Merribeth was also awarded an MBA from Northeastern University.